VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on June 21, 2019, covering events occurring on June 17, 2019, and June 20, 2019. The Company is a biopharmaceutical entity focused on developing therapies, including its oral NMDA receptor glycine site antagonist, AV-101.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance and clinical developments rather than financial performance data.
Material Changes and Events
- Nasdaq Listing Notice: On June 17, 2019, the Company received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share (Rule 5550(a)(2)) due to the closing bid price over the last 30 consecutive business days.
- Listing Status: The notice has no immediate effect on the Company's listing status, which remains fully effective.
- Compliance Timeline: The Company has 180 calendar days (until December 16, 2019) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- Clinical Update: On June 20, 2019, the Company announced positive preclinical results for AV-101 in a primate model for Parkinson's disease, showing significant reduction in levodopa-induced dyskinesia without adverse effects associated with amantadine.
Outlook, Risks, and Contingencies
Delisting Risk: If the Company fails to regain compliance by December 16, 2019, it may be granted a second 180-day period if it meets other listing standards (e.g., market value of publicly held shares). Failure to comply within all allotted periods could result in delisting.
Uncertainty: The Company states there can be no assurance that it will regain compliance with the minimum bid price requirement or maintain compliance with other Nasdaq listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of VistaGen Therapeutics common stock to assess progress toward the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if compliance is achieved.
- Review the attached press release (Exhibit 99.1) for detailed data on the AV-101 preclinical study results.
- Check for future filings regarding the Company's intent to cure the deficiency or applications for a second compliance period.